Sarepta shares soar on FDA's eteplirsen review delay
May 25, 2016 at 08:34 AM EDT
Shares of Sarepta Therapeutics rose more than 20 percent in premarket trading.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.